nicotinamide adenine dinucleotide / GutMicro Cancer Research Results

NAD, nicotinamide adenine dinucleotide: Click to Expand ⟱
Features:
(Nicotinamide adenine dinucleotide) is a vital coenzyme found in all living cells.
• It exists in two forms: oxidized (NAD⁺) and reduced (NADH), playing central roles in redox reactions, energy metabolism, and various signaling pathways.
• NAD⁺ is essential for critical cellular processes, including ATP production, DNA repair (via enzymes like PARPs), and regulation of sirtuins (a family of NAD⁺-dependent deacetylases involved in cellular stress responses and longevity).

NAD⁺ is integral to energy metabolism, redox balance, DNA repair, and cellular regulatory functions—processes that are often dysregulated in cancer.
-It is required for over 500 enzymatic reactions and plays key roles in the regulation of almost all major biological processes

Medicor Cancer Centres offers it:

-involved in glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation.
-NMN is a precursor to nicotinamide adenine dinucleotide (NAD+)
-alternative form of vitamin B, amide of nicotinic acid
-NAD+ levels decline as we age
-high dose NMN promotes ferroptosis through NAM-mediated SIRT1-AMPK-ACC signaling
-At low doses (10 and 20 mM) and prolonged exposure (48 h), NMN increased cell proliferation, but it induced the suppression of cell proliferation at the high dose (100 mM)
-VitB3 and niacin are precursors for the synthesis of NAD in the body

NAD in Cancer Is Dual-Edge
Tumors need NAD+ to sustain:
-Glycolysis (Warburg)
-PARP DNA repair
-Sirtuin survival signaling
-Redox buffering
NAD depletion (via NAMPT inhibition or high PARP consumption) can:
-Collapse ATP
-Increase ROS
-Trigger apoptosis

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 NAD+ salvage pathway (NAMPT → NMN → NAD+) NAD+ pool ↑ supports glycolysis, DNA repair, PARP activity; NAMPT often upregulated Maintains metabolic homeostasis R, G Metabolic support node Many tumors depend on NAMPT-driven NAD+ salvage; NAMPT inhibitors (e.g., FK866) deplete NAD+ and induce energetic collapse.
2 Glycolysis support (LDH-dependent NAD+ recycling) NAD+ regeneration sustains Warburg flux Normal glycolytic tissues also require NAD+ P, R Warburg sustainment LDH converts NADH → NAD+ to maintain glycolytic flux; NAD+ availability is a rate-limiting factor in high glycolysis tumors.
3 PARP-mediated DNA repair (NAD+ consumption) DNA damage repair ↑; therapy resistance ↑ (context) Genome stability maintenance R, G DNA repair capacity PARPs consume NAD+ during DNA repair. PARP inhibitors exploit tumors with HR defects (e.g., BRCA).
4 Sirtuin signaling (SIRT1–7; NAD+-dependent deacetylases) Context-dependent tumor survival or suppression Metabolic regulation, longevity pathways R, G Epigenetic/metabolic modulation Sirtuins require NAD+; effects vary by tumor type (pro-survival in some, suppressive in others).
5 Redox balance (NAD+/NADH ratio) High NAD+/NADH ratio supports anabolic growth Redox homeostasis P, R Redox control Altered NAD+/NADH ratios influence ROS, mitochondrial function, and metabolic flexibility.
6 CD38/CD157 NAD+ degradation NAD+ depletion influences immune and tumor metabolism Immune modulation, aging R, G Immune-metabolic interface CD38 overexpression can lower NAD+ pools; relevant in immune microenvironment contexts.
7 OXPHOS support (mitochondrial NADH supply) NADH fuels ETC; supports mitochondrial ATP production Normal energy metabolism P, R Mitochondrial respiration support NADH oxidation via Complex I regenerates NAD+; OXPHOS-dependent tumors rely on this axis.
8 Therapy resistance modulation NAD+ restoration may reduce oxidative therapy efficacy May protect normal tissue from oxidative injury G Context-dependent NAD+ boosting (e.g., NR, NMN) may theoretically support tumor repair pathways; data mixed and context-specific.
9 NAMPT inhibition (therapeutic strategy) NAD+ depletion → ATP ↓ → apoptosis ↑ Toxicity risk in high-turnover tissues R, G Metabolic collapse NAMPT inhibitors are being explored as anti-cancer metabolic therapies.
10 Bioavailability / supplementation constraint Systemic NAD+ boosting may not selectively target tumor NAD pools Systemic NAD+ supports normal tissue repair — Translation constraint Oral precursors (NR, NMN, niacin) increase systemic NAD+ but tumor-specific impact remains unclear.

TSF: P = 0–30 min (redox flux shifts), R = 30 min–3 hr (metabolic signaling changes), G = >3 hr (gene-level adaptation, repair, phenotype changes).



GutMicro, Gut Microbiota: Click to Expand ⟱
Source:
Type:
Gut microbiome may affect responses to numerous forms of cancer therapy.
The gut microbiota plays a multifaceted role in cancer biology, influencing tumor development, progression, and patient prognosis. Dysbiosis and specific microbial populations have been linked to various cancers, with implications for patient outcomes. While the relationship between gut microbiota and cancer prognosis is an active area of research, it holds promise for the development of microbiome-based biomarkers and therapeutic strategies in oncology.


Scientific Papers found: Click to Expand⟱
2935- NAD,    Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner
- in-vitro, Nor, NA
*GutMicro↑, *OS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Clinical Biomarkers ⓘ

GutMicro↑, 1,  

Functional Outcomes ⓘ

OS↑, 1,  
Total Targets: 2

Scientific Paper Hit Count for: GutMicro, Gut Microbiota
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:268  Target#:350  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page